Rheumatoid Arthritis

Jisna R. Paul; Deepali Sen; Prabha Ranganathan

doi:10.1016/B978-0-12-386882-4.00029-3

Rheumatoid Arthritis

Jisna R. Paul, Deepali Sen, Prabha Ranganathan

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Rheumatoid arthritis (RA) is an inflammatory disease that can cause severe joint destruction and disability, with subsequent high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones of RA treatment. They not only relieve joint pain, swelling, and stiffness but also slow the radiographic progression of disease. Over the last 10-15. years, a new class of disease-modifying medications, biologic agents, has been added to the armementarium of DMARDs, and they are highly effective. However, there remains considerable heterogeneity in patients' response to these agents. Pharmacogenetics may offer a reliable means of predicting an individual patient's response to a given DMARD prior to initiation of therapy. In this chapter, we review the current literature on the pharmacogenetics of traditional and biologic DMARDS in RA. Pharmacogenetics holds the promise of individualizing RA drug therapy.

Original language	English
Title of host publication	Handbook of Pharmacogenomics and Stratified Medicine
Publisher	Elsevier Inc.
Pages	653-681
Number of pages	29
ISBN (Electronic)	9780123868831
ISBN (Print)	9780123868824
DOIs	https://doi.org/10.1016/B978-0-12-386882-4.00029-3
State	Published - May 6 2014

Keywords

Biologic DMARDS
Non-biologic DMARDS
Pharmacogenetics
Rheumatoid arthritis (RA)

Access to Document

10.1016/B978-0-12-386882-4.00029-3

Cite this

@inbook{6d09e09309a04c00bef0bf13babee277,

title = "Rheumatoid Arthritis",

abstract = "Rheumatoid arthritis (RA) is an inflammatory disease that can cause severe joint destruction and disability, with subsequent high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones of RA treatment. They not only relieve joint pain, swelling, and stiffness but also slow the radiographic progression of disease. Over the last 10-15. years, a new class of disease-modifying medications, biologic agents, has been added to the armementarium of DMARDs, and they are highly effective. However, there remains considerable heterogeneity in patients' response to these agents. Pharmacogenetics may offer a reliable means of predicting an individual patient's response to a given DMARD prior to initiation of therapy. In this chapter, we review the current literature on the pharmacogenetics of traditional and biologic DMARDS in RA. Pharmacogenetics holds the promise of individualizing RA drug therapy.",

keywords = "Biologic DMARDS, Non-biologic DMARDS, Pharmacogenetics, Rheumatoid arthritis (RA)",

author = "Paul, {Jisna R.} and Deepali Sen and Prabha Ranganathan",

year = "2014",

month = may,

day = "6",

doi = "10.1016/B978-0-12-386882-4.00029-3",

language = "English",

isbn = "9780123868824",

pages = "653--681",

booktitle = "Handbook of Pharmacogenomics and Stratified Medicine",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Rheumatoid Arthritis

AU - Paul, Jisna R.

AU - Sen, Deepali

AU - Ranganathan, Prabha

PY - 2014/5/6

Y1 - 2014/5/6

N2 - Rheumatoid arthritis (RA) is an inflammatory disease that can cause severe joint destruction and disability, with subsequent high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones of RA treatment. They not only relieve joint pain, swelling, and stiffness but also slow the radiographic progression of disease. Over the last 10-15. years, a new class of disease-modifying medications, biologic agents, has been added to the armementarium of DMARDs, and they are highly effective. However, there remains considerable heterogeneity in patients' response to these agents. Pharmacogenetics may offer a reliable means of predicting an individual patient's response to a given DMARD prior to initiation of therapy. In this chapter, we review the current literature on the pharmacogenetics of traditional and biologic DMARDS in RA. Pharmacogenetics holds the promise of individualizing RA drug therapy.

AB - Rheumatoid arthritis (RA) is an inflammatory disease that can cause severe joint destruction and disability, with subsequent high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones of RA treatment. They not only relieve joint pain, swelling, and stiffness but also slow the radiographic progression of disease. Over the last 10-15. years, a new class of disease-modifying medications, biologic agents, has been added to the armementarium of DMARDs, and they are highly effective. However, there remains considerable heterogeneity in patients' response to these agents. Pharmacogenetics may offer a reliable means of predicting an individual patient's response to a given DMARD prior to initiation of therapy. In this chapter, we review the current literature on the pharmacogenetics of traditional and biologic DMARDS in RA. Pharmacogenetics holds the promise of individualizing RA drug therapy.

KW - Biologic DMARDS

KW - Non-biologic DMARDS

KW - Pharmacogenetics

KW - Rheumatoid arthritis (RA)

UR - http://www.scopus.com/inward/record.url?scp=84942155665&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386882-4.00029-3

DO - 10.1016/B978-0-12-386882-4.00029-3

M3 - Chapter

AN - SCOPUS:84942155665

SN - 9780123868824

SP - 653

EP - 681

BT - Handbook of Pharmacogenomics and Stratified Medicine

PB - Elsevier Inc.

ER -

Rheumatoid Arthritis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this